SLC5A2 and COVID-19: SGLT2 inhibitors were associated with a 10% nonsignificant reduction in COVID-19 hospitalisation (pooled OR 0.90; 95% CI: 0.67–1.20, I2 = 45%, random-effects model), with moderate heterogeneity between studies (Figure 3b).